^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    13h
    FT819 in Subjects With B-cell Malignancies (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • FT819
    14h
    RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Cabaletta Bio | N=12 --> 28 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    21h
    Autologous Bedside CD19 CAR T-cell Therapy for B-ALL (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, The General Hospital of Western Theater Command
    New P1 trial
    1d
    Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. (PubMed, World J Gastroenterol)
    Comparative insights highlight the advantages of liso-cel over other CAR-T cell products, such as axicabtagene ciloleucel and tisagenlecleucel in terms of toxicity, logistics, and outpatient feasibility. With ongoing improvements in manufacturing, accessibility, and biomarker development, liso-cel is well-positioned to become a central component in the evolving treatment paradigm for FL. However, challenges remain regarding durability of response, cost, and access, which warrant careful discussion.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
    1d
    A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Juventas Cell Therapy Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)
    2d
    Long-term Follow up Local Registry Study of Kymriah in South Korea (clinicaltrials.gov)
    P=N/A, N=179, Recruiting, Novartis Pharmaceuticals | N=500 --> 179
    Enrollment change
    |
    Kymriah (tisagenlecleucel-T)
    2d
    Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy. (PubMed, Hemasphere)
    To identify predictive biomarkers, we performed flow cytometry and multiplex assays before and early after CAR-T infusion on 78 patients (ide-cel n = 31; axi-cel n = 24; and cilta-cel n = 23) undergoing CAR-T therapy. Baseline sIL-2R and sVCAM-1 demonstrated robust predictive value for prolonged neutropenia, severe infections, and mortality independently of key clinical variables such as the underlying disease and CAR-T product. Integration of these markers improves existing models and can help to refine risk assessment and guide individualized patient management in CAR-T therapy.
    Journal • IO biomarker
    |
    IL2RA (Interleukin 2 receptor, alpha) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    |
    Yescarta (axicabtagene ciloleucel) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    3d
    PiNACLE-H2H: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (clinicaltrials.gov)
    P3, N=400, Recruiting, Lyell Immunopharma, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • rondecabtagene autoleucel (LYL314)
    3d
    Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL (clinicaltrials.gov)
    P2, N=26, Recruiting, King Hussein Cancer Center
    New P2 trial
    |
    zorpocabtagene autoleucel (MB-CART 19.1)
    4d
    A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 (clinicaltrials.gov)
    P=N/A, N=270, Active, not recruiting, Ruijin Hospital
    New trial • Real-world evidence
    |
    Yorwida (inaticabtagene autoleucel)
    4d
    ODIN: Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta (clinicaltrials.gov)
    P1, N=40, Recruiting, University Health Network, Toronto | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    CD20 negative
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel)
    4d
    NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2028 --> Aug 2028 | Initiation date: Oct 2025 --> Feb 2026 | Trial primary completion date: Jul 2027 --> Nov 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Hyleukin-7 (efineptakin alfa)